PMID- 17666750
OWN - NLM
STAT- MEDLINE
DCOM- 20071023
LR  - 20191026
IS  - 1543-1894 (Print)
IS  - 1543-1894 (Linking)
VI  - 134
DP  - 2007
TI  - Molecular methods used for detection of minimal residual disease following 
      hematopoietic stem cell transplantation in myeloid disorders.
PG  - 161-78
AB  - Monitoring of minimal residual disease (MRD) in patients with acute or chronic 
      myeloid disorders is routinely performed after allogeneic or autologous 
      transplantation. The detection of MRD helps to identify patients who are at high 
      risk for leukemic relapse after transplantation. The most commonly used 
      techniques for MRD detection are qualitative and quantitative PCR methods, 
      fluorescence in situ hybridization (FISH), fluorescence-activated cell sorting 
      (FACS), and cytogenetic analysis, which are often performed complementary in 
      order to assess more precisely MRD. Here, we describe the most used sensitive 
      real-time reverse-transcription (RT)-PCR methods for chronic and acute myeloid 
      disorders. Besides protocols for real-time RT-PCR and multiplex RT-PCR procedures 
      for the most common fusion-gene transcripts in acute and chronic myeloid 
      disorders, methods for detection of disease-specific genetic mutated alterations 
      as FLT3 gene-length mutations, and aberrantly expressed genes as WT1 gene 
      transcripts, are described in detail for daily use.
FAU - Elmaagacli, Ahmet H
AU  - Elmaagacli AH
AD  - Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, 
      Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Med
JT  - Methods in molecular medicine
JID - 101123138
RN  - 0 (AML1-ETO fusion protein, human)
RN  - 0 (CBFbeta-MYH11 fusion protein)
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RUNX1 Translocation Partner 1 Protein)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - EC 2.7.10.1 (FLT3 protein, human)
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
SB  - IM
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 19
MH  - Chromosomes, Human, Pair 6
MH  - Core Binding Factor Alpha 2 Subunit/genetics
MH  - Genes, Wilms Tumor
MH  - Genes, abl
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia, Myeloid/diagnosis/pathology/*therapy
MH  - Molecular Diagnostic Techniques/*methods
MH  - Neoplasm, Residual/*diagnosis
MH  - Oncogene Proteins, Fusion/genetics
MH  - RUNX1 Translocation Partner 1 Protein
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Translocation, Genetic
MH  - fms-Like Tyrosine Kinase 3/genetics
EDAT- 2007/08/02 09:00
MHDA- 2007/10/24 09:00
CRDT- 2007/08/02 09:00
PHST- 2007/08/02 09:00 [pubmed]
PHST- 2007/10/24 09:00 [medline]
PHST- 2007/08/02 09:00 [entrez]
AID - 1-59745-223-8:161 [pii]
AID - 10.1007/978-1-59745-223-6_12 [doi]
PST - ppublish
SO  - Methods Mol Med. 2007;134:161-78. doi: 10.1007/978-1-59745-223-6_12.